Free Trial

InflaRx (IFRX) Competitors

$1.43
0.00 (0.00%)
(As of 05/31/2024 ET)

IFRX vs. SKYE, SBTX, NKTX, NBTX, URGN, QTTB, AVIR, VTYX, KMDA, and LLY

Should you be buying InflaRx stock or one of its competitors? The main competitors of InflaRx include Skye Bioscience (SKYE), Silverback Therapeutics (SBTX), Nkarta (NKTX), Nanobiotix (NBTX), UroGen Pharma (URGN), Q32 Bio (QTTB), Atea Pharmaceuticals (AVIR), Ventyx Biosciences (VTYX), Kamada (KMDA), and Eli Lilly and Company (LLY). These companies are all part of the "pharmaceutical preparations" industry.

InflaRx vs.

InflaRx (NASDAQ:IFRX) and Skye Bioscience (NASDAQ:SKYE) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, media sentiment, dividends, institutional ownership, community ranking and earnings.

InflaRx received 231 more outperform votes than Skye Bioscience when rated by MarketBeat users. However, 100.00% of users gave Skye Bioscience an outperform vote while only 64.19% of users gave InflaRx an outperform vote.

CompanyUnderperformOutperform
InflaRxOutperform Votes
233
64.19%
Underperform Votes
130
35.81%
Skye BioscienceOutperform Votes
2
100.00%
Underperform Votes
No Votes

InflaRx's return on equity of -37.37% beat Skye Bioscience's return on equity.

Company Net Margins Return on Equity Return on Assets
InflaRxN/A -37.37% -33.57%
Skye Bioscience N/A -212.28%-120.36%

InflaRx has a beta of 1.26, indicating that its share price is 26% more volatile than the S&P 500. Comparatively, Skye Bioscience has a beta of 1.74, indicating that its share price is 74% more volatile than the S&P 500.

42.4% of InflaRx shares are owned by institutional investors. Comparatively, 21.1% of Skye Bioscience shares are owned by institutional investors. 16.3% of InflaRx shares are owned by company insiders. Comparatively, 0.7% of Skye Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, InflaRx and InflaRx both had 2 articles in the media. Skye Bioscience's average media sentiment score of 1.24 beat InflaRx's score of 0.96 indicating that Skye Bioscience is being referred to more favorably in the news media.

Company Overall Sentiment
InflaRx Positive
Skye Bioscience Positive

Skye Bioscience has lower revenue, but higher earnings than InflaRx.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InflaRx$70K1,202.83-$46.18M-$0.78-1.83
Skye BioscienceN/AN/A-$37.65MN/AN/A

InflaRx currently has a consensus target price of $13.50, suggesting a potential upside of 844.06%. Skye Bioscience has a consensus target price of $22.00, suggesting a potential upside of 89.49%. Given InflaRx's stronger consensus rating and higher possible upside, research analysts plainly believe InflaRx is more favorable than Skye Bioscience.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
InflaRx
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
3.50
Skye Bioscience
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

InflaRx beats Skye Bioscience on 9 of the 14 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IFRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IFRX vs. The Competition

MetricInflaRxPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$84.20M$6.78B$5.17B$7.99B
Dividend YieldN/A2.65%2.76%4.00%
P/E Ratio-1.8311.32113.7815.26
Price / Sales1,202.83255.152,386.0773.53
Price / CashN/A32.7035.4131.55
Price / Book0.826.085.544.59
Net Income-$46.18M$138.60M$106.07M$213.90M
7 Day Performance-0.69%3.29%1.14%0.87%
1 Month Performance3.62%0.05%0.65%1.82%
1 Year Performance-66.03%-3.68%2.69%5.90%

InflaRx Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SKYE
Skye Bioscience
1.1709 of 5 stars
$12.06
+0.8%
$22.00
+82.4%
+85,267.6%$338.52MN/A0.0011Positive News
SBTX
Silverback Therapeutics
0 of 5 stars
$8.98
+2.0%
N/A+29.3%$323.80MN/A-3.7183
NKTX
Nkarta
2.8295 of 5 stars
$6.44
-1.5%
$17.83
+176.9%
+47.9%$318.24MN/A-2.74150Short Interest ↑
Positive News
NBTX
Nanobiotix
1.5698 of 5 stars
$6.60
-0.2%
$11.00
+66.7%
+34.4%$311.08M$39.18M0.00102Gap Up
URGN
UroGen Pharma
4.031 of 5 stars
$13.24
+3.0%
$46.00
+247.4%
+36.1%$310.53M$82.71M-3.89204Positive News
QTTB
Q32 Bio
2.2712 of 5 stars
$26.00
-11.6%
$49.67
+91.0%
N/A$310.49M$1.16M-0.8037Positive News
AVIR
Atea Pharmaceuticals
0.9717 of 5 stars
$3.66
-0.8%
N/A-10.0%$308.26M$351.37M-1.8774Positive News
VTYX
Ventyx Biosciences
1.8524 of 5 stars
$4.37
-1.8%
$21.75
+397.7%
-85.9%$308.08MN/A-1.3579Positive News
KMDA
Kamada
4.203 of 5 stars
$5.30
+1.5%
$11.00
+107.5%
+11.7%$304.64M$142.52M23.04378Positive News
LLY
Eli Lilly and Company
4.5905 of 5 stars
$807.43
-0.1%
$769.53
-4.7%
+87.9%$767.39B$34.12B118.9143,000Insider Selling

Related Companies and Tools

This page (NASDAQ:IFRX) was last updated on 6/2/2024 by MarketBeat.com Staff

From Our Partners